Risk Factors for JAK-Inhibitor Treatment in Atopic Dermatitis

Ida Vittrup, MD and PhD, Department of Dermatology, Bispebjerg Hospital, Denmark, discusses a cross-sectional study on risk factors, presented at EADV 2023, that could affect the use of JAK-inhibitors in Danish patients with atopic dermatitis. The results reveal the prevalence of various risk factors among the patient population and how they influence the choice of JAK-inhibitor treatment.